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Functional Recovery Analyses in 500 Patients Treated With Coronary 
Angioplasty for Acute Myocardial Infarction 
STEPHEN G. ELLIS, MD, FACC, WILLIAM W. O’NEILL. MD, FACC, 
ERIC R. BATES, MD, FACC, JOSEPH A. WALTON, JR., MD, FACC, 
ELIZABETH G. NABEL, MD, FACC, STEVEN W. WERNS, MD, FACC, 
ERIC J. TOPOL, MD, FACC 
Ann Arbor, Michigun 
The in-hospital course of 500 consecutive patients treated 
with coronary angioplasty for acute myocardial infarction 
was reviewed in relation to their clinical and angiographic 
presentation and angioplasty outcome to deterniine which 
patients benefit most from successful angioplasty in this 
setting. Patient age was 56 + 11 years (mean +- SD) and 
78% were men; 46% had anterior myocardial infarction, 
49% received concomitant intravenous thrombolytic ther- 
apy, left ventricular ejection fraction was 47 f 11% and 
median time to angioplasty was 4.7 h (range 1 to 24). 
Angioplasty was successful in 78% of patients and partially 
successful in 7% of patients; the overall in-hospital mortal- 
ity rate was 10.2%. 
Multivariate analysis found six independent correlates 
(p < 0.05) of in-hospital mortality: left ventricular ejection 
fraction 530%, lack of postangioplasty infarct artery pa- 
tency, age >65 years, recurrent ischemia after successful 
angioplasty, emergency bypass surgery and arterial pres- 
sure on admission to the catheterization laboratory ~100 
mm Hg. After consideration of these predictors of survival 
in multivariate analyses, angioplasty success still was inde- 
pendently correlated with improved in-hospital survival for 
patients with cardiogenic shock (p = 0.002) and anterior 
Recent randomized trials (I ,2) have shown that most pa- 
tients with acute myocardial infarction treated with throm- 
bolytic therapy in the form of recombinant tissue-type plas- 
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myocardial infarction (p = 0.007). A trend toward an 
independent beneficial effect of successful ahgioplasty on 
survival was also noted in patients with inferior wall 
infarction and precordial ST segment depression (p = 
0.063) and for all patients who were hypotensive on admis- 
sion to the catheterization laboratory, regardless of the 
infarct site (p = 0.057). 
Multivariate analysis revealed two independent corre- 
lates (p < 0.05) of improved ejection fraction at hospital 
discharge: collateral vessels beyond thP coronary occlusion 
site and baseline ejection fraction 540%. After correction 
for the effect of these variables, successful angioplasty still 
imparted a modest improvement in ejection fraction for 
patients wlth inferior myocardial infarction treated within 
4 h of symptom onset (p = O.OSS), but a significant 
improvement in ejection fraction lvas not present for pa- 
tients with anterior infarction or for patients with inferior 
iniarction treated >4 h after symptom onset. These data 
allow for stratification of patients in the emergency room to 
grobps that are most likely or unlikely to derive benefit 
from immediate cardiac catheterization and coronary 
angioplasty. 
(.I Am Co11 Cardio11989;13:12.51-9) 
minogen activator (rt-PA) do not benefit from emergency 
cardiac catheterization and coronary angioplasty. However, 
given that ~13% of patients with acute infarction will have 
contraindications to intravenous thrombolytic therapy other 
than late presentation (3), the difficulty of clinically deter- 
mining the occurrence of reperfusion (4), the 25% to 65% 
failure rate for currently available thrombolytic agents (1,.5) 
and the clear survival benefit of reperfusion therapy (3), it 
was hypothesized that some patients might benefit from 
early cardiac catheterization and angioplasty. To identify 
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which patients might most benefit from emergency coronary 
angioplasty in the setting of acute myocardial infarction, the 
in-hospital survival add recovery of 500 consecutive patients 
treated with angioplasty were reviewed in relation to their 
presenting clinical and angiographic characteristics and to 
success or failure of the angioplasty procedure. 
Methods 
Study patients. Five hundred consecutive patients with 
available procedural cineangiograms treated by coronary 
angioplasty for acute myocardial infarction within 24 h of 
symptom onset at the University of Michigan from Decem- 
ber 22, 1983 until June 17, 1988 form the study group. 
Patients were excluded only if the procedural cineangiogram 
was unavailable for review (n = 19). On the basis of 
in-hospital mortality, incidence of bypass surgery and clini- 
cal characteristics, there was no bias of ascertainment in- 
duced by the nonavailability of cineangiograms. One hun- 
dred seven of the patients participated in previously reported 
(1,6,7) or ongoing randomized trials assessing interventions 
in acute myocardial infarction. In these studies, 105 patients 
received intravenous recombinant tissue-type plasminogen 
activator (rt-PA) before angioplasty, 9 patients received 
intravenous rt-PA and urokinase and 2 patients received 
intravenous streptokinase. In addition, on the basis of clin- 
ical indications, 110 patients received intravenous streptoki- 
nase and 3 patients received rt-PA before angioplasty, and 
271 patients were treated with angioplasty alone. In all 
cases, angioplasty was performed after the patient provided 
informed consent and under guidelines approved by the 
Committee to Review Clinical Research and Investigation at 
the University of Michigan Medical Center. 
Indications for angioplasty. Four hundred eighty-two pa- 
tients underwent coronary angioplasty on the basis of per- 
sistent total occlusion, clinical evidence of ongoing ischemia 
or hemodynamic compromise. Eighteen patients without 
apparent ongoing ischemia were randomly assigned to im- 
mediate coronary angioplasty after apparently successful 
thrombolysis. 
Patients were not considered for angioplasty if they had 
left main coronary artery disease with ~60% diameter ste- 
nosis, 270% stenosis of both the proximal left anterior 
descending and left circumflex coronary arteries or distal 
occlusion in a tortuous vessel that was believed to be 
technically unsuitable for the procedure. Patients were not 
necessarily excluded because of advanced age or poor left 
ventricular function and, in fact, the concurrent presence of 
clinically evident left ventricular dysfunction and persistent 
chest pain often prompted referral for cardiac catheteriza- 
tion. However, patients were excluded from receiving 
thrombolytic agents for age >75 years, cardiogenic shock or 
time from chest pain to treatment >6 h. 
Angioplasty technique. All patients received sublingual 
nitroglycerin (0.4 mg) in the emergency room to exclude 
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coronary spasm. Intravenous morphine was administered as 
required for chest pain. After the placement of a vascular 
sheath, 3,000 to 5,000 U of heparin was administered intra- 
venously. Once it was determined that a patient’s coronary 
anatomy was suitable for angioplasty, an additional 5,000 to 
7,000 U of intravenous heparin was given, and in 137 
patients, 5 mg of intravenous verapamil was administered. 
Intracoronary nitroglycerin (0.2 mg) was also commonly 
administered during the procedure. 
Coronary angioplasty was performed by one of several 
staff interventional cardiologists of varied experience (mean 
480 2 419 angioplasty procedures performed). Selective 
coronary angiography was performed in both the right and 
the left anterior oblique projections with use of multiple 
degrees of angulation and cranial-caudal obliquity. Contrast 
ventriculography was performed in the 30” right anterior 
oblique projection before completion of the procedure. After 
the initial coronary angiograms were obtained, a 0.014 or 
0.016 in. steerable guide wire was advanced through a guide 
catheter to the coronary stenosis. The guide wire was used 
to probe the occlusion gently and, if little or no resistance 
was met, it was guided through the stenosis. The balloon 
catheter was advanced and inflated serially until an adequate 
reduction of the stenosis had been accomplished. 
Patients were then treated with heparin for 3 to 10 days, 
aspirin (80 to 600 mg daily) and an oral calcium channel 
blocker and nitrates as tolerated. One hundred fifty-six 
patients were also maintained on an infusion of low molec- 
ular dextran (40 ml/h) for 24 h. The vascular sheath was left 
in place for 24 h, at which time, if the patient was in clinically 
stable condition, heparin administration was stopped for 2 to 
3 h and the sheath removed. The heparin infusion was 
resumed after hemostasis had been achieved at the groin 
puncture site. 
All patients were initially monitored in the intensive care 
unit. Hemodynamic monitoring was performed and adjunc- 
tive treatment was administered as clinically indicated. 
Clinical variables analyzed. Clinical data had been pro- 
spectively entered on case report forms at the time of 
catheterization. These forms and patient charts were re- 
viewed by an independent observer, unaware of angio- 
graphic and in-hospital outcome, to assure completeness and 
accuracy of the data. Ten clinical variables were analyzed: 
age, gender, diabetes mellitus, prior myocardial infarction, 
infarct site (anterior or inferior/posterior), precordial ST 
segment depression (rl mm in two or more of electrocar- 
diographic (ECG) leads V, to V, for patients with inferior or 
posterior infarction), time from onset of chest pain to coro- 
nary angioplasty, prior use of intravenous thrombolytic 
agents, systolic blood pressure on arrival in the cardiac 
catheterization laboratory and the presence of cardiogenic 
shock (defined as postfluid administration systolic blood 
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pressure 580 mm Hg without or 189 mm Hg with the use of 
intravenous inotropic agents or balloon counterpulsation 
support). 
Angiographic variables analyzed. The following angio- 
graphic variables were also recorded prospectively without 
knowledge of outcome: coronary vessel and site dilated, 
preangioplasty diameter stenosis, preangioplasty Throm- 
bolysis in Myocardial Infarction (TIMI) flow grade (4). the 
presence of collateral vessels beyond the site to be dilated, 
the number of major epicardial vessels with ~50% stenosis 
and left ventricular ejection fraction. Percent diameter ste- 
nosis was measured with a previously described and vali- 
dated automated system (81, except in those procedures in 
which the final postangioplasty angiogram had the angio- 
plasty guide wire placed across the stenosis, in which case 
hand-held calipers were used to measure the stenosis. Ejec- 
tion fraction was measured by the area-length method (CLC 
version 6A. VVF analysis. Electronics for Medicine). 
Procedural and follow-up variables analyzed. The follow- 
ing procedural variables were entered prospectively at the 
time of catheterization by an observer unaware of clinical 
outcome, and follow-up variables were determined by pa- 
tient chart and follow-up cineangiogram analysis by an 
observer unaware of the initial quantitative angioplasty 
result. These variables were postangioplasty percent diam- 
eter stenosis, postangioplasty TIMI flow grade, procedural 
success (postangioplasty diameter stenosis <70% and TIM1 
flow grade ~2) in the culprit stenosis, intermittent vessel 
patency during angioplasty, postangioplasty recurrent isch- 
emia (defined as recurrent ischemic events requiring either 
further angioplasty or bypass surgery, or resulting in a 
second increase in creatine kinase [CK] MB isoenzyme 
levels or silent total occlusion at the site dilated. found on 
predischarge angiography). emergency bypass surgery and 
in-hospital death. 
Statistical analysis. All data were entered into the Uni- 
versity of Michigan Angioplasty in Acute Myocardial Infarc- 
tion Database, a relational database using SYSTAT software 
(Wilkinson, Leland. SYSTAT: The System for Statistics; 
Evanston, Illinois, SYSTAT Inc., 1986). Data are presented 
as mean values ? SD, except where noted. Unpaired Stu- 
dent’s t tests and chi-square analyses, using the Yates 
correction and Fisher’s exact test where applicable. were 
used to compare continuous and categorical single variables 
with outcome. The analyses of the effects of successful 
coronary angioplasty on in-hospital mortality and left ven- 
tricular functional recovery in various patient subsets were 
performed as follows. First. the independent correlates of 
mortality and functional recovery were determined from all 
variables with use of multiple stepwise linear regression 
analysis. The independent effect of angioplasty success on 
outcome was then determined by adjusting for the significant 
covariates by forcing them into the logistic regression equa- 
tion and then entering the variable angioplasty success to 
assess the effect of the procedural result on outcome. 
Multiple logistic regression analysis with alpha to enter and 
remove variables = 0.15 (9) was used to assess the indepen- 
dent effect of variables on in-hospital mortality and left 
ventricular ejection fraction. Probability (p) values of ~0.05 
were considered significant, although values of 0.05 < p 2 
0.10 are included for completeness (IO). 
The pcrtient subsets chosen prospectively for the analysis 
qf the qfect of coronary mngioplusty success on mortality 
Il’ere (IS jk~llo~~s. For unterior myocardial infarction: all 
patients, patients 565 years of age. >65 years, with cardio- 
genie shock, with no prior thrombolytic therapy, with prior 
thrombolytic therapy, with total occlusion (TIM1 flow grade 
<I), with no total occlusion, with time to treatment 14 h, 
with time to treatment 56 h, with time to treatment 512 h, 
with time to treatment I3 to 24 h, with arterial pressure on 
admission to the catheterization laboratory < 100 mm Hg and 
with arterial pressure ~100 mm Hg. For inferior myocardiul 
injktion. the same subsets were prospectively chosen with 
the addition of patients with precordial ST segment depres- 
sion and without precordial ST segment depression. The 
effect of successful coronary angioplasty on patients in 
cardiogenic shock and with blood pressure <IO0 mm Hg, 
regardless of infarct location, was also assessed. The patient 
subsets prospectively chosen for analysis of the effect of 
successful coronary angioplasty on recovery of left ventric- 
ular function were anterior infarction of 54 h duration, 
anterior infarction of 4. I to 24 h duration. inferior infarction 
of 54 h duration and inferior infarction of 4.1 to 24 h 
duration. 
Results 
Patient characteristics (Table 1). Of particular importance 
for comparison with results from other series, the median 
time to treatment in this series was 4.7 h. 49% of patients had 
prior treatment with thrombolytic agents, 18% had prior 
myocardial infarction and 12% exhibited signs of cardiogenic 
shock. The coronary stenosis features are also listed in Ta- 
ble I. 
Angioplasty results (Table 2). Successful dilation of the 
primary coronary stenosis was achieved in 78.4% of pa- 
tients, and partial success was achieved in an additional 
6.85%. Success rates for various patients subsets ranged from 
69% in patients with cardiogenic shock (only 50% success if 
triple vessel disease was also present) to 88% if intravenous 
thrombolytic therapy had been received. Procedural success 
was independently predicted (p < 0.05) by preangioplasty 
TIM1 coronary flow grade ~2, no triple vessel disease and 
left ventricular ejection fraction >30%. 
Ischemia or restenosis necessitating a prehospital dis- 
charge intervention occurred in 14.4% of all patients, and the 
overall in-hospital mortality rate was 10.2%. 
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Table 1. Clinical and Coronary Stenosis Characteristics in 
500 Patients 
Patients 
Age 56 f 11 
Gender (% male) 78.4 
Anterior myocardial infarction (%) 46.2 
Time to angioplasty (median, range) (h) 4.7 (I to 24) 
Prior myocardial infarction (%) 17.9 
Prior intravenous thrombolytic therapy (%) 48.7 
Multivessel coronary artery disease (%) 54.7 
Systolic blood pressure before angioplasty (mm Hg) 114 + 22 
LVEF (%) 47 + II 
Cardiogenic shock (%) 11.9 
Stenoses (n = 530) 
Artery (%) 
Left anterior descending 46.4 
Left circumflex 10.4 
Right coronary 42.1 
Bypass graft 1.1 
Site (%) 
Proximal 46.7 
Mid or distal 53.3 
Total occlusion (%)* 60.0 
Preangioplasty % diameter stenosis 91 ? 13 
Preangioplasty TIM1 grade 1.1 ? 1.2 
*TIMI grade = 0 or 1. LVEF = left ventricular ejection fraction; TIM1 = 
Thrombolysis in Myocardial Infarction trial flow grade. 
Causes and timing of death. There were 51 in-hospital 
deaths (10.2%) in these 500 patients. The immediate causes 
of death were pump failure in 30 patients, ventricular 
arrhythmia in 8, pulmonary complications in 4, electrome- 
chanical dissociation in 3, central nervous system hemor- 
rhage in 1 patient and other or incompletely determined 
causes in 5 patients, Seven (13.7%) of the 51 deaths occurred 
in the cardiac catheterization laboratory, and an additional 
23 deaths (45.1%) occurred within the first 24 h after cardiac 
catheterization. 
Predictors of in-hospital mortality (Table 3). Failure of 
angioplasty to restore infarct artery patency was more 
strongly associated with in-hospital mortality than was fail- 
ure to achieve procedural success (final percent stenosis 
<70% and TIMI grade ~2). If coronary patency was not 
entered into the multivariate analysis, procedural success 
replaced it as an independent predictor of in-hospital sur- 
vival (p = 0.052). However, if the definition of procedural 
success was changed to require a final percent diameter 
stenosis <50%, it was not a significant independent predictor 
of survival. 
Patient subsets with improved survival after reperfusion by 
coronary angioplasty (Table 2). The overall in-hospital mor- 
tality rate for patients with anterior myocardial infarction 
treated by coronary angioplasty was 13.4%, whereas for 
patients with inferior myocardial infarction, it was 7.4% 
(9.6% for patients with precordial ST segment depression 
and 6.1% for patients without precordial ST segment depres- 
sion) (p = NS). If patients often excluded from thrombolytic 
trials (age >70 years, cardiogenic shock and treatment >6 
hours after chest pain onset [ 1,5,6]) were removed from the 
analysis, the mortality rate for patients with anterior infarc- 
tion (n = 128) was 8.6%, and for those with inferior infarc- 
tion (n = 170), it was 4.1% 
After correction for the multivariate predictors of in- 
hospital survival, successful angioplasty still appeared to 
benefit patients with anterior myocardial infarction (p = 
0.007) but, in general, patients with inferior myocardial 
infarction did not benefit (Fig. 1). Patients with inferior 
infarction and precordial ST segment depression did exhibit 
a trend toward benefit with successful angioplasty (p = 
0.063), whereas no benefit was seen in patients without 
precordial ST segment depression (mortality coefficient 
0.057 t 0.057, p = 0.32). Patients who were hypotensive on 
admission to the cardiac catheterization laboratory (arterial 
pressure <IO0 mm Hg), regardless of infarct site, may have 
benefited from successful angioplasty (p = 0.057). 
For patients presenting in cardiogenic shock, postangio- 
plasty coronary patency (TIM1 flow grade 22) was a stron- 
ger independent correlate of survival than was procedural 
success. After consideration of the effects of left ventricular 
ejection fraction and patient age (the other independent 
correlates of outcome), postangioplasty coronary patency 
decreased the mortality rate by 44% (p = 0.002). Given the 
particular importance of coronary patency in this subgroup 
of patients, the independent correlates of patency after 
angioplasty were determined and found to be triple vessel 
disease (coefficient -0.54 2 0.13, p 5 0.001) time to 
angioplasty >6 h (coefficient -0.28 2 0.11, p = 0.01) and 
prior use of thrombolytic agents (coefficient 0.26 -+ 0.12, p = 
0.04), with a constant = 0.85. In Table 4, these survival 
results are compared with results in several recent studies 
utilizing conventional (that is, nonthrombolytic) therapy. 
Improvement in ejection fraction (Tables 5 and 6). Two 
hundred eighty-nine (64.3%) of the 449 hospital survivors 
had follow-up cardiac catheterization before hospital dis- 
charge. After correction for the influence of collateral ves- 
sels beyond the coronary occlusion site and baseline ejection 
fraction, both of which independently correlated with im- 
provement in ejection fraction, successful angioplasty was 
modesty correlated with improved ejection fraction recovery 
in patients with inferior infarction treated within 4 h of 
symptom onset, but was not correlated with functional 
recovery in the other patient subgroups studied. 
Discussion 
Recent clinical trials in acute myocardial infarction have 
demonstrated that reperfusion therapy improves patient 
survival and left ventricular functional recovery (3,11,12), 
but that, in general, patients undergoing successful reperfu- 
sion with recombinant tissue-type plasminogen activator 
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Table 2. Effect of Angioplasty Procedural Success on Mortality in Patient Subgroups 
Patient Subgroup 
Angioplasty Mortality Mortality Multivariate Independent Predictors Multivariate 
n % Success With Success With Failure Coefficient (k SD) of Mortality p Value 
Anterior MI 
565 yr 
>6S yr 
Cardiogenic shock 
No thrombolytic 
therapy 
Thrombolytic 
therapy 
TIM1 flow -il 
TIM1 flow r2 
Treatment 54 h 
Treatment 56 h 
Treatment 512 h 
Treatment I3 to 24 h 
Arterial pressure < 100 
mm Hg 
Arterial pressure 2 100 
mm Hg 
Inferior Ml 
565 years 
>65 years 
Cardiogenic shock 
No thrombolytic 
therapy 
Thrombolytic therapy 
TIMI flow 51 
TIMI flow 22 
Precordial ST 
depression 
No precordial ST 
depression 
Treatment 54 h 
Treatment 56 h 
Treatment 5 I2 h 
Treatment I3 to 24 h 
Arterial pressure : 100 
mm Hg 
Arterial pressure z 100 
mm Hg 
231 78.3 7.2 36.0 
186 79.5 6.1 27.0 
45 73.3 12.1 66.7 
33 60.6 15.0 76.‘) 
12x 74.2 6.4 13.’ 
103 83.5 8.1 23.5 
I38 71.0 8.2 42.5 
91 89.2 6.0 10.0 
83 81.9 7.3 33.0 
I51 80.7 8.2 27.6 
I98 19.2 7.8 30.0 
33 72.7 4.2 66.7 
64 70.3 II.1 63. I 
167 81.4 5.9 19.3 
279 77.8 7.0 14.7 
218 77.5 4.8 8.5 
61 78.7 12.5 30.8 
28 78.6 13.6 50.0 
143 73.4 7.6 21.0 
136 82.4 6.3 4.3 
I78 71.9 10.1 18.4 
IO1 88.1 2.2 0.0 
II5 72.2 6.0 18.X 
I48 82.4 6.6 3.x 
I22 79.5 7.2 8.0 
207 78.7 5.5 9.1 
230 77.4 5.1 I I.5 
49 79.6 14.8 28.6 
67 80.6 12.9 38.5 
!I? 76.9 4.9 8.3 
-0.13 2 0.05 
~0.03 + 0.05 
--0.56 + 0.14 
-0.10 _f 0.12 
~0.13 ? 0.06 
~0. I I ? 0.08 
~0.13 2 0.06 
+0.02 + 0.09 
~0.0.5 5 0.01 
-0.06 t 0.06 
PO.07 + 0.05 
PO.35 2 0.13 
--0.20 -’ 0.10 
PO.1 I ? 0.05 
0 + 0.04 
-0.01 2 0.04 
10.02 + 0.13 
-0.19 + 0.20 
-0.04 + 0.06 
--0.05 * 0.05 
-0.01 + 0.06 
~0.01 ? 0.03 
-0.09 + 0.06 
to.06 + 0.06 
to.02 2 0.06 
10.02 f 0.04 
-0.02 i- 0.04 
to.16 i 0.29 
-0.12 r 0.17 
to.03 ? 0.04 
EF 530. BP CIOO’ 
EF 530, BP cl00 
K 
EF 230. BP < 100 
EF 530. BP < 100. 
0.007 
NS 
0.001 
NS 
0.024 
CABG 
EF 530. K 0.09 
EF 530. BP <IO0 0.028 
R. CABG NS 
EF 530 NS 
EF 530. K. CABG NS 
EF 430. K. CABG 0.096 
BP <lOO, EF 530 0.007 
EF 530. CABG 0.024 
R. age >65 year5 0.017 
BP <lOO. CABG. age. NS 
R. EF 130 
EF 530, CABG 
K. BP i 100 
age >65 yr. EF 530 
BP <lOO, age >65 yr. R, 
NS 
NS 
NS 
NS 
CABG 
EF 530. CABG NS 
BP 5100. age >65 yr, NS 
EF 530 
CABG. R 
BP %lOO. EF 530 
NS 
0.063 
R, CABG. age i65 yr NS 
age >65 yr. BP < 100. K NS 
CABG. BP <IO0 NS 
CABG. BP < 100 NS 
age >65 yr. K NS 
age >65 yr NS 
CABG. EF 530. K NS 
*BP < 100 = arterial blood pressure <lOO mm Hg on arrival at the cardiac catheterization laboratory. CABG = coronary artery bypass graft surgery: 
EF 530 = left ventricular ejection fraction ~30%: Ml = myocardial infarction: K = recurrent ischemia after successful coronary angioplasty: other abbreviations 
as in ‘Table I 
(rt-PA) do not benefit from immediate coronary angioplasty 
(1,2). However, it is not known whether the 25% to 65% of 
patients failing to achieve reperfusion with available throm- 
bolytic agents (1.5) or the ~13% (3) of patients who have 
contraindications to thrombolytic therapy might have im- 
proved survival or improved ventricular contractility after 
expediently performed angioplasty. Because limited health 
care resources preclude transfer of all patients with acute 
infarction for immediate cardiac catheterization and possible 
coronary angioplasty, this study was undertaken to deter- 
mine which patient subgroups might benefit most from such 
a strategy. 
Previous studies on angioplasty for acute myocardial in- 
farction. Prior studies of angioplasty for acute myocardial 
infarction (13-18) have reported results from a relatively 
small number of patients and have not reported results from 
different clinical subsets of patients. In fact, detailed subset 
analysis has infrequently been reported from most recent 
intervention trials (1,2,19,20), with the exception of Gruppo 
Italian0 per lo Studio della Streptochinasi nell’lnfarto Mio- 
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Table 3. Independent Correlates of In-Hospital Mortality* 
Variable 
LVEF ~30% 
Postangioplasty coronary 
patency (TIM1 flow 22) 
Age >65 yr 
Recurrent ischemia after 
successful angioplasty 
Emergency bypass surgery 
Arterial pressure 2100 mm Hg 
Constant = 0.154 
Multivariate 
Coefficientt 
Multivariate 
p Value 
0.196 2 0.045 
-0.124 + 0.040 
0.096 t 0.031 
0.108 + 0.035 
0.136 + 0.055 
-d.O80 ? 0.039 
<O.OOl 
0.002 
0.002 
0.003 
0.013 
0.039 
*Proximal left anterior descending coronary stenosis (coefficient = 0.054 
? 0.032; p = 0.088) and total coronary occlusiofl before angioplasty (coeffi- 
cient = 0.044 2 0.026; p = 0.089) were of borderline significance. +The 
coefficient directly estimates the increased risk of death, for example, for left 
ventricular ejection fraction (LVEF) ~30%; 0.196 equates with an increased 
risk of 19.6% from 15.4%. or a 35.0% in-hospital mortality rate. TIM1 = 
Thrombolysis in Myocardial Infarction trial flow grade. 
cardico (GISSI) (3). In the largest angioplasty series reported 
to date, Stack et al. (13) reported an 87% procedural success 
rate for angioplasty performed after intravenous streptoki- 
nase administration in 216 patients, a 12% mortality rate 
independently related to the presence of cardiogenic shock, 
older age, poor left ventricular function and female gender 
and improved ejection fraction in patients with successful 
persistent coronary reperfusion. The mortality rate with 
successful angioplasty was 11.8%, and with failed angio- 
plasty it was 13.8%. Rothbaum et al. (14), reporting results 
from 151 patients, demonstrated improved survival with 
successful angioplasty in univariate analysis, but did not 
report results of either multivariate or subset analysis. 
Adequate assessment of the value of “rescue” angio- 
plasty is not available from current trials because of the 
common exclusion of high risk patients and the small num- 
ber of patients studied- (for example, the power of the 
Thrombolysis in Myocardial Infarction-HA Study [22] to 
40- 
35- 
30- 
* 
.f: 5 25- 
5 20- 
I 15- 
S 
lo- 
p = .007*1 
detect a 50% improvement in survival with rescue angio- 
plasty at a p value of 0.05 is only 0.15, or one chance in 
almost seven). 
Results in the $esent series. The in-hospital course of 500 
patients, datinH from our earliest experience with angio- 
plasty in this !@&ing, was reviewed. Patients were not 
excluded because of advanced age or poor left ventricular 
function and, in fact, patients in this series appear to have 
had a higher incidence of adverse risk factors compared with 
that ili many recently reported randomized thrombolytic 
trials that often exclude extremely ill patients (1,2,3,6,19,20, 
22). Prdtedural success was achieved in 78% of patients, 
with an overall 10.2% ih-hospital mortality rate. This success 
rate is comparable with those reported in other large series 
(14,15), considering the documented overestimation of suc- 
cess rates with visual cineangiographic analysis compared 
with the objective quantitative method used in this analysis 
(23). Mortality was independently predicted by ejection 
fraction <30%, angioplasty failure, age >65 years, recurrent 
ischemia after successful angioplasty, need for emergency 
bypass surgery and hypotension at presentation to the car- 
diac catheterization laboratory. Overall, improvement in left 
ventricular contractility was modest (+ 1.5 ? 9.4 ejection 
fraction units). Improvement was correlated with the pres- 
ence of demonstrable collateral vessels and baseline ejection 
fraction ~40%. Importantly, to best predict both survival 
and left ventricular recovery, angioplasty success did not 
require a r&luction in percent diameter stenosis to 150%; 
rather, the restoration of TIM1 grade r2 flow provided the 
optimal separation of patients who improved from those who 
did not. 
Patients with anterior infarction. Patients with anterior as 
opposed to inferior myocardial infarction have generally had 
a greater survival benefit from reperfusion reported in stud- 
ies employing varied thrombalytic agents (3,20,24). In this 
series, overall mortality was lower than in most recently 
reported series in which reperfusion was not attempted 
Figure 1. Mortality rate with successful angioplasty 
(PTCA) (solid bars) and failed angioplasty (batched bars) 
for patients with anterior (Ant) and inferior myocardial 
infarction (MI). Probability (p) values refer to the inde- 
pendent effect of angioplasty success after Consideration 
I p = NS’ 1 
of the other independent predictors of mortality (Tables 
2 and 4). ST = presence of precordial ST segment 
depression. Multivariate p value after correction for 
other significant predictors of outcome. 
PTCA: success Fallurc 
Anterior MI 
Succrss Failure success Failure 
lnterlor MI lnferlor MI 
wlth Ant ST wlthout Ant ST 
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Table 4. Comparison of In-Hospital Mortality Rate After Angioplasty With Results of Conventional Therapy in Various Patient Subsets 
Angioplasty Angioplasty Overall Thanavaro 
success Failure Angioplasty GISSI (5) (40) ISAM (19) ICWW (20) 
Study characteristics 
No. of patients - so0 i.XS? 1,105 XX? 116 
LVEF (%,) - - 47 2 II NA NA NA 492 13 
Prior Ml (%‘r) - 17.9 15.2 0.0 11.5 NA 
Shock (%l - - 11.9 2.3 10.9 NA 2.6 
Subgroup mortality I%) 
Anterior Ml 7.2 36.0 13.4 18.4 15.6 17.4 28.3 
Inferior MI” 7.0 14.7 7.4 7.2 9.1 4.6 7.9 
Cardiogenic shock 14.3 72.2 32.2 70. I NA NA NA 
*Various authors (41-43): mortality with precordial ST segment depression and conventional therapy = 15.7%. without ST segment depression = 2.2%. Note: 
This study and thar of Thanavaro et al. (40) report in-hospital mortality. whereas the mortality shown for GISSI (3) is at 21 days and that for the yestern 
Washington (ICWW) study (20) is 30 days. GISSI = Gruppo Italian0 per lo Studio della Streptochinasi nell’lnfarto Miocardico: ISAM = Intravenous 
Streptokinase in Acute Myocardial Infarction trial; LVEF = left ventricular ejection fraction; MI = myocardial infarction: NA = not available. 
(Table 4). and successful angioplasty was an independent 
predictor of improved survival regardless of time to treat- 
ment. This benefit was most pronounced in patients who had 
not received prior thrombolytic therapy. in patients >65 
years of age and in those with marked initial impairment of 
coronary blood flow (TIM1 coronary flow grade 0 or 1). 
Although there was no significant benefit to those who had 
received thrombolytic therapy, the estimated absolute sur- 
vival benefit of I 1.3 -C 8.5% (p = 0.09) suggests merit to the 
concept of “rescue” angioplasty (8). 
Patients with inferior infarction. In this analysis, after 
consideration was given to other important predictors of 
outcome, successful angioplasty did not appear to provide a 
survival benefit in patients with inferior infarction, although 
patients with precordial ST segment depression had a sug- 
gested benefit (p = 0.06). The improvement in ejection 
fraction demonstrated in patients treated within 4 h of 
symptom onset suggests that an improvement in survival for 
such patients might have been demonstrated if more had 
been enrolled for analysis. These results are consistent with 
those from other trials (12,25) that limited treatment to 
patients seen very early in the course of their infarction. 
Difficulty in proving benefit from reperfusion in patients with 
inferior infarction may’ relate to the smaller infarcts with 
right or left circumflex coronary artery occlusion compared 
Table 5. Independent Correlates of Improved Ejection Fraction 
From Baseline to Prehospital Discharge* 
Correlate Multivariate Coefficientt 
Collateral vessels 2.8 ? I.5 
LVEF ~40% 2.6 2 I.6 
Multivariate p Value 
0.034 
0.054 
*From right anterior oblique projection: patients with left circumflex 
coronary stenoses excluded. Postangioplasty arterial patency (coefficient = 
4.9 ? 3.3. p = 0.07) and recurrent ischemia after successful angioplasty 
(coefficient = -2.4 ? 2.2, p = 0.14) were of borderline significance. +In 
ejection fraction units. Abbreviations as in Table I, 
with infarct size in left anterior descending coronary occlu- 
sion, to the higher mortality rate associated with anterior 
infarction even after correction for infarct size or possibly to 
a different response of the right ventricle or inferior wall 
myocardium to reperfusion (26-28). We noted that rapid 
angioplasty-induced reperfusion in 10 patients with proximal 
right coronary artery occlusion led to marked electrical 
instability (recurrent ventricular fibrillation) or functional 
compromise (electromechanical dissociation or hypotension 
without bradycardia) compared with findings in the prere- 
perfUsion state. One cannot be certain that angioplasty in 
larger numbers of patients with inferior infarction might not 
have led to a survival advantage in other patient groups but, 
in this series, multivariate analysis did not demonstrate even 
a strong trend toward improved survival in patients with or 
without thrombolytic therapy or in patients with occlusion of 
the proximal right coronary artery or any other site. 
Patients with cardiogenic shock. Patients with cardiogenic 
shock did not benefit from intravenous streptokinase in the 
GISSI trial (3) and it has been suggested (24) that thrombo- 
lytic agents are less effective in patients with shock. Several 
anecdotal reviews (29-32) have suggested that patients with 
cardiogenic shock, expected to have a 10% to 30% survival 
rate when treated conventionally (5,33), might benefit from 
coronary angioplasty. These results have not been subjected 
to comprehensive analysis. In our series. with use of an 
aggressive approach with angioplasty of the infarct-related 
Table 6. Effect of Successful Angioplasty Procedure on Ejection 
Fraction Improvement in Patient Subgroups 
Subgroup Coefficient* Multivariate p Value 
Anterior infarction 54 h +2.5 + 7.2 NS 
Anterior infarction 4.1 to 24 h t4.0 ? 9.2 NS 
Inferior infarction 54 h is.2 + 3.2 0.055 
Inferior infarction 4.1 to 24 h i2.9 _t 3.4 NS 
“In ejection fraction units. 
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artery, followed by angioplasty to other critical stenoses if 
the patient continued to have hemodynamic compromise or 
apparent ischemia, 67.8% of patients survived, and an ex- 
pected absolute 44% improvement in survival was apparent 
when angioplasty restored TIM1 flow grade r2 to the 
infarct-related artery (p = 0.002). However, restoration of 
coronary patency was unlikely in patients with triple vessel 
disease, particularly if they were treated >6 h after symptom 
onset, and these patients may do better with other ap- 
proaches to treatment. 
Benefit from angioplasty success or harm with angioplasty 
failure? This was not a randomized trial of coronary angio- 
plasty and, as such, one must question whether the appar- 
ently improved survival after successful angioplasty was 
derived from the benefits of reperfusion or whether angio- 
plasty failure somehow worsened clinical outcome. Several 
mechanisms by which reperfusion might enhance survival 
have been suggested (34-36), but there remains a lingering 
concern about the possible harmful effects of rapid reperfu- 
sion in this setting (37,38). We can only critically analyze our 
results and compare them with other series to try to answer 
this question. This is especially difficult because the likeli- 
hood of angioplasty success has been shown to be inversely 
related to the presence of triple vessel disease and ejection 
fraction 530% (39), factors that independently predict poor 
survival. For patients with anterior myocardial infarction, 
the overall 13% mortality rate appears better than that in 
most series in which patients were treated conventionally 
(3,17,18,38), especially given the relatively high incidence of 
adverse risk factors present in patients in our series. How- 
ever, the 36% mortality rate in patients with failed angio- 
plasty is higher than that reported in other series, suggesting 
possible harm from failed angioplasty. The overall survival 
of patients with inferior myocardial infarction treated with 
coronary angioplasty in this series was no better than that 
reported with conventional therapy, and the 16% mortality 
rate with failed angioplasty is higher than that recorded in 
most other series, leading to the conclusion that failed 
angioplasty may have worsened survival in some patients. 
Interestingly, these data did not demonstrate a particular 
benefit from early versus late reperfusion, as was noted in 
the GISSI trial (3). 
Limitations of study. The results of this study should be 
considered in light of several limitations to the analysis. 
First, this is not a randomized trial of coronary angioplasty 
versus conventional or thrombolytic therapy, and only a 
relative benefit of successful versus failed angioplasty can be 
determined. Further conclusions utilizing historical compar- 
isons must be considered as extrapolations from the results. 
Second, the large number of statistical comparisons may 
have led to spurious, apparently significant results (multiple 
comparison problem). A critical appraisal of these results in 
relation to results from other studies should minimize this 
problem. Third, the relatively small number of patients 
studied makes it possible, if not likely, that a benefit from 
successful reperfusion with angioplasty might have been 
overlooked in some patients. Fourth, patients received dif- 
ferent adjunctive treatments with angioplasty, and the re- 
sults may not be fully applicable to different combinations of 
therapy (for example, angioplasty and rt-PA compared with 
angioplasty and rt-PA plus urokinase [S]). However, the use 
or type of thrombolytic therapy was not an independent 
predictor of mortality in this series. Finally, these results are 
based on comparisons of in-hospital survival and ejection 
fraction data only, and do not take into consideration the 
importance of improving survival or quality of life over a 
longer follow-up period. 
Clinical implications. Until one can determine with a high 
degree of certainty whether reperfusion has been established 
in patients treated with thrombolytic therapy for acute 
myocardial infarction, it is suggested from these data that 
strong consideration be given to early cardiac catheteriza- 
tion in patients with anterior myocardial infarction or car- 
diogenic shock to determine the status of the infarct-related 
artery because successful angioplasty appears to impart 
benefit to these patients if TIM1 flow grade 51 is present. 
Similar patients who have contraindications to thrombolytic 
therapy also would appear to benefit. Patients with inferior 
infarction and precordial ST segment depression or those 
seen early enough in the course of their infarction to permit 
angioplasty within 4 h of symptom onset may also possibly 
benefit from this strategy. However, failed angioplasty may 
impair survival, and angioplasty should not be undertaken 
when there is not a high likelihood of success. Finally, the 
absence of demonstrable benefit in patients with successful 
thrombolysis underscores the need to develop techniques for 
noninvasively assessing restoration of coronary blood flow 
in this setting. 
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